Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Stomach Neoplasms/drug therapy/pathology"'
Autor:
Al-Batran, Salah-Eddin, Homann, Nils, Pauligk, Claudia, Goetze, Thorsten O, Meiler, Johannes, Kasper, Stefan, Kopp, Hans-Georg, Mayer, Frank, Haag, Georg Martin, Luley, Kim, Lindig, Udo, Schmiegel, Wolff, Pohl, Michael, Stoehlmacher, Jan, Folprecht, Gunnar, Probst, Stephan, Prasnikar, Nicole, Fischbach, Wolfgang, Mahlberg, Rolf, Trojan, Jörg, Koenigsmann, Michael, Martens, Uwe M, Thuss-Patience, Peter, Egger, Matthias, Block, Andreas, Heinemann, Volker, Illerhaus, Gerald, Moehler, Markus, Schenk, Michael, Kullmann, Frank, Behringer, Dirk M, Heike, Michael, Pink, Daniel, Teschendorf, Christian, Löhr, Carmen, Bernhard, Helga, Schuch, Gunter, Rethwisch, Volker, von Weikersthal, Ludwig Fischer, Hartmann, Jörg T, Kneba, Michael, Daum, Severin, Schulmann, Karsten, Weniger, Jörg, Belle, Sebastian, Gaiser, Timo, Oduncu, Fuat S, Güntner, Martina, Hozaeel, Wael, Reichart, Alexander, Jäger, Elke, Kraus, Thomas, Moenig, Stefan Paul, Bechstein, Wolf O, Schuler, Martin, Schmalenberg, Harald, Hofheinz, Ralf D, FLOT4-AIO Investigators
Publikováno v:
The Lancet, Vol. 393, No 10184 (2019) pp. 1948-1957
Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and docetaxel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1400::0b9cf264bfe92e55766adcd35c21e6e4
https://archive-ouverte.unige.ch/unige:134616
https://archive-ouverte.unige.ch/unige:134616
Autor:
R. Morant, Richard Herrmann, Nicola Fazio, F. de Braud, Cristiana Sessa, A. Goldhirsch, Roger Stupp, Rudolf Maibach, Markus Borner, Arnaud Roth
Publikováno v:
Roth, A. D.; Maibach, R.; Fazio, N.; Sessa, C.; Stupp, R.; Morant, R.; Herrmann, R.; Borner, M. M.; Goldhirsch, A.; De Braud, F. (2004). 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere®)–cisplatin in advanced gastric carcinoma: a phase I–II trial. Annals of oncology, 15(5), pp. 759-764. Oxford University Press 10.1093/annonc/mdh187
Annals of Oncology, vol. 15, no. 5, pp. 759-64
Annals of Oncology, Vol. 15, No 5 (2004) pp. 759-64
Annals of Oncology, vol. 15, no. 5, pp. 759-64
Annals of Oncology, Vol. 15, No 5 (2004) pp. 759-64
BACKGROUND: A phase I-II multicenter trial was conducted to define the maximum tolerated dose (MTD) according to tolerance and toxicity (primary objective), as well as to describe the clinical activity, in terms of response and survival (secondary ob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e630f32445f6aac050b713c3557c2574
Autor:
Arnaud Roth
Publikováno v:
Annals of Oncology, Vol. 14, No 2 (2003) pp. 175-7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e032a3220778a9b4b6357955bacaa37
https://doi.org/10.1093/annonc/mdg081
https://doi.org/10.1093/annonc/mdg081
Autor:
Arnaud D. Roth
Publikováno v:
Gastric Cancer, Vol. 5 Suppl 1 (2002) pp. 27-9
The combination of docetaxel with cisplatin in gastric cancer is a promising development. In a phase II study, 85-100 mg/m2 docetaxel plus 75 mg/m2 cisplatin was established as an active regimen in advanced gastric cancer (with an overall response ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42ca94613596ce4ff265c80c43db938d
https://doi.org/10.1007/s10120-002-0204-5
https://doi.org/10.1007/s10120-002-0204-5
Autor:
Rob Glynne-Jones, Rudolf Maibach, Kaspar Rufibach, Piercarlo Saletti, Martin Leslie, Stephen Falk, Arnaud Roth, Dieter Köberle, M. Wernli, Nicola Fazio, Lukas Widmer, Markus Borner, Filippo de Braud, Matthew T. Seymour, Jürg Bernhard, Roger Stupp
Publikováno v:
Journal of Clinical Oncology, Vol. 25, No 22 (2007) pp. 3217-23
Purpose This randomized phase II trial evaluated two docetaxel-based regimens to see which would be most promising according to overall response rate (ORR) for comparison in a phase III trial with epirubicin-cisplatin-fluorouracil (ECF) as first-line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fc72cf3b01b8c3dab6959c97108233d
https://pubmed.ncbi.nlm.nih.gov/17664469
https://pubmed.ncbi.nlm.nih.gov/17664469
To reduce the Hickman line-associated morbidity of continuous infusion 5-fluorouracil combined with epirubicin and cisplatin (ECF) and to investigate the need for infusional regimens, we conducted a retrospective study in patients with advanced gastr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10561::e054fb52143724a18c7ab886fb38e0aa
http://olympias.lib.uoi.gr/jspui/handle/123456789/19731
http://olympias.lib.uoi.gr/jspui/handle/123456789/19731
Autor:
Roukos, D. H.
Gastric cancer is still a major health problem and a leading cause of cancer mortality despite a worldwide decline in incidence. Environmental and Helicobacter pylori (Hp) acting early in life in a multistep and multifactorial process may cause intes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10561::b4de13b626411a91726448e8717b5fca
http://olympias.lib.uoi.gr/jspui/handle/123456789/22674
http://olympias.lib.uoi.gr/jspui/handle/123456789/22674